secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-020699
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT reports Q1 net loss $28.7M; cash runway into H1 2026 after $129M offering
------------------------------------------------------------------------------

- Net loss $28.7M for Q1 2023 vs $26.3M in Q1 2022; R&D expenses $22.4M.
- Cash, equivalents and marketable securities $202M as of March 31, 2023; plus $129M net from May 2023 offering.
- Positive interim data from 4D-150 Phase 1/2 PRISM trial for wet AMD: 100% injection-free at 36 weeks in 3E10 cohort.
- Acquired worldwide rights to sCFH from Aevitas for 4D-175 (geographic atrophy) candidate.
- Enrollment of Phase 2 dose expansion for 4D-150 expected to complete Q3 2023; initial data H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017023020699/0000950170-23-020699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017023020699/fdmt-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer